Agios Pharmaceuticals
AGIO
189 hedge funds and large institutions have $3.03B invested in Agios Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 61 reducing their positions, and 36 closing their positions.
25% more call options, than puts
Call options by funds: $28.6M | Put options by funds: $22.9M
13% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 61
0.37% more ownership
Funds ownership: 102.97% → 103.34% (+0.37%)
6% less funds holding
Funds holding: 201 → 189 (-12)
22% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 36
25% less capital invested
Capital invested by funds: $4.06B → $3.03B (-$1.03B)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$167M |
| 2 |
BlackRock
New York
|
+$54.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$29.8M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$24.8M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
-$149M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$71.7M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$15.2M |
| 4 |
JP Morgan Chase
New York
|
-$12.9M |
| 5 |
CGT
Capital Guardian Trust
Los Angeles,
California
|
-$8.69M |
AGIO Hedge Fund Activity: Q2 2019 in Review
189 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2019, worth a combined $3.03B — down 25% from $4.06B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AGIO and 28 opened new positions — a net loss of 8 holders — while 61 trimmed existing stakes and 69 added.
The largest buyer was Bellevue Group, opening a new position worth an estimated $167M. The largest seller was Woodford Investment Management, exiting entirely with an estimated $149M sold.
- 189 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2019, down from 201 in Q1 2019.
- Funds reported $3.03B of Agios Pharmaceuticals stock for Q2 2019, down 25% quarter-over-quarter.
- 28 funds opened new Agios Pharmaceuticals positions in Q2 2019 and 36 closed out, a net change of -8 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2019 was Bellevue Group, an estimated $167M added.
- The largest Agios Pharmaceuticals seller in Q2 2019 was Woodford Investment Management, an estimated $149M sold.
Based on aggregated 13F filings for Q2 2019.